Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walid F Gellad

Showing results (21-30 of 265) with videos related to

Pageof 27
Sort By:
JAMA Oncology|May 1, 2018
Total Costs of Chimeric Antigen Receptor T-Cell ImmunotherapyInmaculada Hernandez, Vinay Prasad, Walid F Gellad
JAMA Oncology|October 17, 2018
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-ReplyInmaculada Hernandez, Vinay Prasad, Walid F Gellad
JAMA|September 8, 2018
Lowering the P Value ThresholdInmaculada Hernandez, Walid F Gellad, Chester B Good
JAMA Internal Medicine|July 4, 2017
Limitations Concerning the Association of Physician Sex and Patient OutcomesMark W Friedberg, Walid F Gellad, Vinay Prasad
JAMA Internal Medicine|January 15, 2019
Assessment of Spending in Medicare Part D If Medication Prices From the Department of Veterans Affairs Were UsedBrett Venker, Kevin B Stephenson, Walid F Gellad
The New England Journal of Medicine|April 5, 2019
A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part DWalid F Gellad, Molly Ennis, Courtney C Kuza
JAMA Dermatology|August 14, 2020
Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical CompaniesLaura K Ferris, Walid F Gellad, Inmaculada Hernandez
JAMA|September 1, 2015
Modernizing Medicaid Managed Care: Can States Meet the Data Challenges?Philip Rocco, Walid F Gellad, Julie M Donohue
JAMA Health Forum|October 11, 2022
Cost and Access Implications of Defining CAR-T Therapy as a DrugRohan Chalasani, Tina B Hershey, Walid F Gellad
JAMA Internal Medicine|March 10, 2020
The Skyrocketing Cost of Rectal IndomethacinB Joseph Elmunzer, Inmaculada Hernandez, Walid F Gellad
Pageof 27

Showing results (21-30 of 265) with videos related to

Sort By:
Pageof 27
JAMA Oncology|May 1, 2018
Total Costs of Chimeric Antigen Receptor T-Cell ImmunotherapyInmaculada Hernandez, Vinay Prasad, Walid F Gellad
JAMA Oncology|October 17, 2018
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-ReplyInmaculada Hernandez, Vinay Prasad, Walid F Gellad
JAMA|September 8, 2018
Lowering the P Value ThresholdInmaculada Hernandez, Walid F Gellad, Chester B Good
JAMA Internal Medicine|July 4, 2017
Limitations Concerning the Association of Physician Sex and Patient OutcomesMark W Friedberg, Walid F Gellad, Vinay Prasad
JAMA Internal Medicine|January 15, 2019
Assessment of Spending in Medicare Part D If Medication Prices From the Department of Veterans Affairs Were UsedBrett Venker, Kevin B Stephenson, Walid F Gellad
The New England Journal of Medicine|April 5, 2019
A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part DWalid F Gellad, Molly Ennis, Courtney C Kuza
JAMA Dermatology|August 14, 2020
Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical CompaniesLaura K Ferris, Walid F Gellad, Inmaculada Hernandez
JAMA|September 1, 2015
Modernizing Medicaid Managed Care: Can States Meet the Data Challenges?Philip Rocco, Walid F Gellad, Julie M Donohue
JAMA Health Forum|October 11, 2022
Cost and Access Implications of Defining CAR-T Therapy as a DrugRohan Chalasani, Tina B Hershey, Walid F Gellad
JAMA Internal Medicine|March 10, 2020
The Skyrocketing Cost of Rectal IndomethacinB Joseph Elmunzer, Inmaculada Hernandez, Walid F Gellad
Pageof 27